Sanara MedTech Inc. Announces the Publication of a 5,335 Patient Study Demonstrating a Significant Reduction in Surgical Site Infections When Activated Collagen (CellerateRX® Surgical Powder) Was Used to Promote Wound Healing
30 Novembre 2023 - 3:15PM
Sanara MedTech Inc
. Based in Fort Worth, Texas,
Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”)
(NASDAQ: SMTI), a medical technology company focused on developing
and commercializing transformative technologies to improve clinical
outcomes and reduce healthcare expenditures in the surgical,
chronic wound and skincare markets, announced today that the
Journal of Surgery has published a retrospective study on
CellerateRX® Surgical Powder (“CellerateRX”) titled “Activated
Collagen Powder Significantly Reduces Surgical Site Infections in
Patients Undergoing Elective Surgery”.
Zach Fleming, Sanara’s CEO stated, “This study
demonstrates that the use of CellerateRX can have a significant
impact on surgical patients’ outcomes by promoting wound healing
and helping to prevent surgical site infections. We believe these
results align with our mission of improving outcomes while lowering
costs and support the benefits of using CellerateRX as documented
in previous studies. Based in part on this study, we also believe
that CellerateRX can be used in surgeries across multiple
specialties to help prevent surgical site infections and positively
impact outcomes.”
About the Study and Key
Results
- Retrospective
study of 5,335 patients undergoing elective surgeries over four
years. More than a quarter of the patients received CellerateRX in
evaluation of clean (76%) or clean contaminated (24%) cases.
- Surgical
specialties included general, surgical oncology, orthopedic,
vascular, neurosurgery, cardiothoracic, plastic and
gynecology.
- The use of
activated collagen (CellerateRX) in patients undergoing elective
surgery resulted in a 59% reduction in surgical site infection
rates. This reduction was most pronounced in the clean cases with a
69% decrease in surgical site infection rates.
Dr. Ryan Nowrouzi and Dr. Samir Awad, the lead
investigators of the study, commented on the significance of the
research, stating “Surgical site infections can lead to morbidity,
mortality, and increased healthcare costs. This study demonstrates
that activated collagen (CellerateRX) can be safely used in
elective surgical procedures to promote wound healing of incisions
with an associated decrease in the rate of surgical site infections
following surgery.”
Click Here to the view the full Journal of
Surgery article on this study. The study was partially funded by a
grant from a subsidiary of the Company.
About
CellerateRX® Surgical
Powder
CellerateRX® is Type I bovine
activated collagen and contains no additives. It is indicated for
use in the management of acute and chronic wounds, including
surgical wounds, partial- and full-thickness wounds, traumatic
wounds, venous stasis ulcers, arterial ulcers, diabetic ulcers, and
first- and second-degree burns.
About Sanara MedTech Inc.
With a focus on improving patient outcomes
through evidence-based healing solutions, Sanara MedTech Inc.
markets, distributes and develops surgical, wound and skincare
products for use by physicians and clinicians in hospitals, clinics
and all post-acute care settings and offers wound care and
dermatology virtual consultation services via telemedicine.
Sanara’s products are primarily sold in the North American advanced
wound care and surgical tissue repair markets. Sanara markets and
distributes CellerateRX® Surgical Activated Collagen®, FORTIFY TRG®
Tissue Repair Graft and FORTIFY FLOWABLE® Extracellular Matrix as
well as a portfolio of advanced biologic products focusing on
ACTIGEN™ Verified Inductive Bone Matrix, ALLOCYTE® Plus
Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix,
TEXAGEN® Amniotic Membrane Allograft, and BIASURGE™ Advanced
Surgical Solution to the surgical market. In addition, the
following products are sold in the wound care market: BIAKŌS®
Antimicrobial Skin and Wound Cleanser, BIAKŌS™ Antimicrobial Wound
Gel, BIAKŌS® Antimicrobial Skin and Wound Irrigation Solution and
HYCOL® Hydrolyzed Collagen. Sanara’s pipeline also contains
potentially transformative product candidates for mitigation of
opportunistic pathogens and biofilm, wound re-epithelialization and
closure, necrotic tissue debridement and cell compatible
substrates. The Company believes it has the ability to drive its
pipeline from concept to preclinical and clinical development while
meeting quality and regulatory requirements. Sanara is constantly
seeking long-term strategic partnerships with a focus on products
that improve outcomes at a lower overall cost. In addition, Sanara
is actively seeking to expand within its six focus areas of wound
and skin care for the acute, post-acute, and surgical markets. The
focus areas are debridement, biofilm removal, hydrolyzed collagen,
advanced biologics, negative pressure wound therapy products and
the oxygen delivery system segment of the wound and skincare
markets.
Information about Forward-Looking
Statements
The statements in this press release that do not
constitute historical facts are “forward-looking statements,”
within the meaning of and subject to the safe harbor created by the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by terms such as “aims,” “anticipates,”
“believes,” “contemplates,” “continue,” “could,” “estimates,”
“expect,” “forecast,” “guidance,” “intend,” “may,” “plan,”
“possible,” “potential,” “predicts,” “preliminary,” “projects,”
“seeks,” “should,” “targets,” “will” or “would,” or the negatives
of these terms, variations of these terms or other similar
expressions. These forward-looking statements include, among
others, statements regarding the ability of CellerateRX to be used
in surgeries across multiple specialties, the development of new
products, the timing of commercialization of our products, the
regulatory approval process and expansion of the Company’s business
in telehealth and wound care. These items involve risks,
contingencies and uncertainties such as the extent of product
demand, market and customer acceptance, the effect of economic
conditions, competition, pricing, uncertainties associated with the
development and process for obtaining regulatory approval for new
products, the ability to consummate and integrate acquisitions, and
other risks, contingencies and uncertainties detailed in the
Company’s SEC filings, which could cause the Company’s actual
operating results, performance or business plans or prospects to
differ materially from those expressed in, or implied by these
statements.
All forward-looking statements speak only as of
the date on which they are made, and the Company undertakes no
obligation to revise any of these statements to reflect the future
circumstances or the occurrence of unanticipated events, except as
required by applicable securities laws.
Investor Contact:
Callon Nichols, Director of Investor
Relations713-826-0524CNichols@sanaramedtech.com
SOURCE: Sanara MedTech Inc.
Grafico Azioni Sanara MedTech (NASDAQ:SMTI)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Sanara MedTech (NASDAQ:SMTI)
Storico
Da Giu 2023 a Giu 2024